1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.
Google Scholar | Crossref | Medline2. Ledermann, JA . First-line treatment of ovarian cancer: questions and controversies to address. Ther Adv Med Oncol 2018; 10: 1–8.
Google Scholar | SAGE Journals3. Chandra, A, Pius, C, Nabeel, M, etal. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med 2019; 8: 7018–7031.
Google Scholar | Crossref | Medline4. Aichinger, G, Lichtenberger, F-B, Steinhauer, TN, etal. The aza-analogous benzo[c]phenanthridine P8-D6 Acts as a dual topoisomerase I and II poison, thus exhibiting potent genotoxic properties. Molecules 2020; 25: 1524.
Google Scholar | Crossref | Medline5. Pommier, Y, Barcelo, JM, Rao, VA, etal. Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol 2006; 81: 179–229.
Google Scholar | Crossref | Medline6. Deweese, JE, Osheroff, N. The DNA cleavage reaction of topoisomerase II: Wolf in sheep’s clothing. Nucleic Acids Res 2009; 37: 738–748.
Google Scholar | Crossref | Medline | ISI7. Meier, C, Steinhauer, TN, Koczian, F, etal. A dual topoisomerase inhibitor of intense pro-apoptotic and antileukemic nature for cancer treatment. Chem Med Chem 2017; 12: 347–352.
Google Scholar | Crossref | Medline8. National Cancer Institute (NCI) . DTP homepage: Cancer Screen 09/2014: NCI-60 DTP Human Tumor Cell Line Screen [The National Cancer Institute (NCI) is gratefully acknowledged for its excellent screening service.], 2014, http://dtp.nci.nih.gov
Google Scholar9. Edmondson, R, Broglie, JJ, Adcock, AF, etal. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol 2014; 12: 207–218.
Google Scholar | Crossref | Medline | ISI10. Goodman, TT, Olive, PL, Pun, SH. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int J Nanomedicine 2007; 2: 265–274.
Google Scholar | Medline | ISI11. Kimlin, LC, Casagrande, G, Virador, VM. In vitro three-dimensional (3D) models in cancer research: an update. Mol Carcinog 2013; 52: 167–182.
Google Scholar | Crossref | Medline12. Lagies, S, Schlimpert, M, Neumann, S, etal. Cells grown in three-dimensional spheroids mirror in vivo metabolic response of epithelial cells. Commun Biol 2020; 3: 1–10.
Google Scholar | Crossref | Medline13. Kurbacher, CM, Korn, C, Dexel, S, etal. Isolation and culture of ovarian cancer cells and cell lines. Methods Mol Biol 2011; 731: 161–180.
Google Scholar | Crossref | Medline14. Hedemann, N, Herz, A, Schiepanski, JH, etal. ADAM17 inhibition increases the impact of cisplatin treatment in ovarian cancer spheroids. Cancers 2021; 13: 2039.
Google Scholar | Crossref15. Ölander, M, Wiśniewski, JR, Flörkemeier, I, etal. A simple approach for restoration of differentiation and function in cryopreserved human hepatocytes. Arch Toxikol 2018; 93: 819–829.
Google Scholar | Crossref16. Huang, X, Weimer, J, von Wurmb-Schwark, N, etal. Alteration of STR profiles in ovarian carcinoma cells during primary culture. Arch Gynecol Obstet 2016; 294: 369–376.
Google Scholar | Crossref | Medline17. Plitzko, B, Havemeyer, A, Kunze, T, etal. The pivotal role of the mitochondrial amidoxime reducing component 2 in protecting human cells against apoptotic effects of the base analog N6-hydroxylaminopurine. J Biol Chem 2015; 290: 10126–10135.
Google Scholar | Crossref | Medline18. Kaufmann, SH . Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 1991; 51: 1129–1136.
Google Scholar | Medline19. Bertrand, RO’, O’Connor, PM, Kerrigan, D, etal. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 1992; 28A: 743–748.
Google Scholar | Crossref | Medline20. Camacho, KM, Kumar, S, Menegatti, S, etal. Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid. J Control Release 2015; 210: 198–207.
Google Scholar | Crossref | Medline21. van Gijn, R, Lendfers, RRH, Schellens, JHM, etal. Dual topoisomerase I/II inhibitors. J Oncol Pharm Pract 2000; 6: 92–108.
Google Scholar | SAGE Journals22. Sehouli, J, Sommer, H, Klare, P, etal. A randomized multicenter phase III trial of topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine for second-line treatment of recurrent ovarian cancer. J Clin Oncol 2006; 24: 5030.
Google Scholar | Crossref23. Abudou, M, Zhong, D, Wu, T, etal. Topotecan for ovarian cancer. Cochrane Database Syst Rev 2008; 2008: CD005589.
Google Scholar24. Markman, M . Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity. Oncologist 2005; 10: 695–697.
Google Scholar | Crossref | Medline25. Aronson, JK (eds). Side effects of drugs annual 27: Cytostatic drugs. 1st ed. Amsterdam: Elsevier Science, 2004.
Google Scholar26. Skok Zidar, ŽN, Kikelj, D, Ilaš, J. Dual inhibitors of human DNA topoisomerase II and other cancer-related targets. J Med Chem 2020; 63: 884–904.
Google Scholar | Crossref | Medline27. Denny, WA, Baguley, BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem 2003; 3: 339–353.
Google Scholar | Crossref | Medline28. van Gijn, R, ten, Bokkel, Huinink, WW, Rodenhuis, S, etal. Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study. Anticancer Drugs 1999; 10: 17–23.
Google Scholar | Crossref | Medline29. Abigerges, D, Armand, JP, Chabot, GG, etal. Phase I and pharmacology study of intoplicine (RP60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs 1996; 7: 166–174.
Google Scholar | Crossref | Medline30. Ewesuedo, RB, Iyer, L, Das, S, etal. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol 2001; 19: 2084–2090.
Google Scholar | Crossref | Medline31. Salerno, S, Da Settimo, F, Taliani, S, etal. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. Curr Med Chem 2010; 17: 4270–4290.
Google Scholar | Crossref | Medline32. Kummar, S, Gutierrez, ME, Anderson, LW, etal. Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol 2013; 72: 917–923.
Google Scholar | Crossref | Medline | ISI33. Mucci-LoRusso, P, Polin, L, Bissery, MC, etal. Activity of batracylin (NSC-320846) against solid tumors of mice. Invest New Drugs 1989; 7: 295–306.
Google Scholar | Crossref | Medline | ISI34. King, PD, Perry, MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162–176.
Google Scholar | Crossref | Medline | ISI35. Bookman, MA, Brady, MF, McGuire, WP, etal. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J Clin Oncol 2009; 27: 1419–1425.
Google Scholar | Crossref | Medline | ISI36. Ding, D, Kong, W-m. Analysis of relative factors of bone marrow suppression after chemotherapy with carboplatin and paclitaxel on the patients with ovarian cancer. Zhonghua Fu Chan Ke Za Zhi 2011; 46: 188–192.
Google Scholar | Medline37. Li, X-R, Zhu, Y, Zhang, G-N, etal. The impact of pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials. J Ovar Res 2021; 14: 9.
Google Scholar | Medline38. Rowinsky, EK, Grochow, LB, Hendricks, CB, etal. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647–656.
Google Scholar | Crossref | Medline39. Abushahin, F, Singh, DK, Lurain, JR, etal. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 2008; 108: 53–57.
Google Scholar | Crossref | Medline | ISI40. Miao, M, Deng, G, Luo, S, etal. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecol Oncol 2018; 148: 286–290.
Google Scholar | Crossref | Medline41. Moore, K, Oza, A, Colombo, N, etal. FORWARD I (GOG 3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Ann Oncol 2019; 5: 403.
Google Scholar | Crossref42. Murai, J, Pommier, Y. PARP trapping beyond homologous recombination and platinum sensitivity in cancers. Annu Rev Cancer Biol 2019; 3: 131–150.
Google Scholar | Crossref43. Hall, SR, Goralski, KB. ZATT, TDP2, and SUMO2: breaking the tie that binds TOP2 to DNA. Transl Cancer Res 2018; 7: 439–444.
Google Scholar | Crossref